CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
Ulipristal Acetate Tablets +1 moredrug
Likely dose
Ulipristal Acetate Tablets 90mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05216952
NCT05216952Phase 2Completed
CompareCT.gov

Ulipristal Acetate for Use in Early Pregnancy Loss: A Phase 2 Pilot Feasibility Study

University of North Carolina, Chapel Hill·interventional·Posted Feb 1, 2022·Updated Jun 28, 2023

In Brief

A Phase 2 clinical trial evaluating Ulipristal Acetate Tablets and Misoprostol Pill for Missed Abortion and 2 related conditions. Completed, enrolled 3 participants across 4 sites.

Detailed Summary

The investigators will study the feasibility of using 90mg ulipristal acetate, a selective progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical management of early pregnancy loss. Patients will be followed to assess effective treatment of early pregnancy loss, additional interventions needed, side effects, adverse events and patient acceptability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMissed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy
CountriesUnited States
CollaboratorsNorth Carolina Translational and Clinical Sciences Institute

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedFeb 1, 2022
Enrollment StartMay 11, 2022
Primary CompletionJan 3, 2023
Study CompletionApr 30, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.4 years ago

Interventions

Ulipristal Acetate Tabletsdrug

90mg (three 30mg tablets) administered orally once

Misoprostol Pilldrug

800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate